Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  General Surgery
  •  Obstetrics Surgery
  •  Gastroenterological Surgery
  •  Endocrine Surgery
  •  Urology
  •  Orthopaedic Surgery
  •  Emergency Surgery
  •  Pediatric Surgery

Abstract

Citation: Clin Surg. 2021;6(1):3339.Research Article | Open Access

Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy by Video-Assisted Surgery for Pleural Malignancies: Technical Aspects and Safety Profile

Francesco Londero1#, Gianluca Masullo1#, William Grossi1, Elisa De Franceschi1, Jacqueline Cinel1, Nicola Vernaccini2, Nunzio Davide de Manna1, Stefano Bacchetti2, Igor Vendramin1, Gianluigi Adani2, Angelo Morelli1 and Enrico Maria Pasqual2*

1Department of Cardiothoracic Surgery, Azienda Sanitaria Universitaria Friuli Centrale, University Hospital Santa Maria della Misericordia, Italy
2Department of General Surgery, Center for Advanced Surgical Oncology, Azienda Sanitaria Universitaria Friuli Centrale, University Hospital Santa Maria della Misericordia, Italy
#These authors contributed equally to this work

*Correspondance to: Enrico Maria Pasqual 

 PDF  Full Text DOI: 10.25107/2474-1647.3339

Abstract

Background: Pleural malignancies are challenging conditions in terms of possibility of cure. Recent growing interest towards Hyperthermic Intrathoracic Chemotherapy (HITHOC) after Cytoreductive Surgery (CRS) has been referred. Minimally invasive approach (VATS) may be suggest in this context but evidence is still lacking. Methods: A preliminary experience in seven patients submitted to cytoreductive surgery and HITHOC is described, with a focus on technical aspects related to VATS approach, operating median time and postoperative complication. Results: A triportal VATS approach has been employed in all cases. Median time of surgery including pleural perfusion was 200 min (range 165 to 370). Mean blood loss was 217 cc (range 100 and 600). Thirty days mortality was nothing. Conclusion: VATS cytoreductive surgery and HITHOC is a safe procedure and could be proposed in the setting of a multimodality strategy employing adjuvant radio-chemotherapy in referral centers.

Keywords

Pleura; Mesothelioma; Thymoma; HITHOC; Cytoreductive surgery; VATS

Cite the article

Londero F, Masullo G, Grossi W, De Franceschi E, Cinel J, Vernaccini N, et al. Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy by Video-Assisted Surgery for Pleural Malignancies: Technical Aspects and Safety Profile. Clin Surg. 2021; 6: 3339.

Search Our Journal

Journal Indexed In

Articles in PubMed

Risk Factors for Visual Impairment in an Uninsured Population and the Impact of the Affordable Care Act
 PubMed  PMC  PDF  Full Text
Antimicrobial Peptides: A Potential Therapeutic Option for Surgical Site Infections
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Review of the Latest Methods in the Treatment of Epidermolysis Bullosa and Other Chronic Wounds, Development of Innovative Advanced Therapy Medicinal Product
 Abstract  PDF  Full Text
Could Collaboration between Emergency Department Clinicians and Dentists More Effectively Treat Patients with Acute Dental Pain?
 Abstract  PDF  Full Text
View More...